Form 4: Royalty Pharma Director Ted W. Love Acquires Shares Through Stock Award

Director Ted W. Love acquired 9,293 Class A Ordinary Shares of Royalty Pharma plc through a restricted stock unit award.

Summary

• On June 7, 2024, Ted W. Love, a director of Royalty Pharma plc, acquired 9,293 Class A Ordinary Shares.
• The acquisition was a result of a restricted stock unit award under the Issuer's 2020 Independent Director Equity Incentive Plan.
• The restricted stock units generally vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
• Following the transaction, Love directly owns 46,234 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally viewed as a positive sign, indicating confidence in the company. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Industry Context

This filing is a routine disclosure of a director's stock ownership change, common in publicly traded companies. It reflects part of the company's compensation strategy to align director interests with shareholder value.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates